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ABSTRACT Mechanistic insights to viral replication and
pathogenesis generally have come from the analysis of viral gene
products, either by studying their biochemical activities and
interactions individually or by creating mutant viruses and
analyzing their phenotype. Now it is possible to identify and
catalog the host cell genes whose mRNA levels change in response
to a pathogen. We have used DNA array technology to monitor
the level of '6,600 human mRNAs in uninfected as compared
with human cytomegalovirus-infected cells. The level of 258
mRNAs changed by a factor of 4 or more before the onset of viral
DNA replication. Several of these mRNAs encode gene products
that might play key roles in virus-induced pathogenesis, identi-
fying them as intriguing targets for further study.
Human cytomegalovirus (HCMV) has the potential to alter
cellular gene expression though multiple mechanisms. Its initial
interaction with the cell surface could initiate a regulatory signal;
indeed, the virion gB and gH glycoproteins induce cellular
transcription factors when added to uninfected cells (1). Constit-
uents of the virion, such as the tegument protein, pp71, migrate
to the nucleus and activate transcription after infection (2), and
viral proteins synthesized after infection, such as the immediate
early 1 and 2 proteins, modulate transcription (3–5). The virus
encodes several G protein-coupled receptors (6, 7) that likely
initiate gene regulatory signal cascades in response to ligands, and
HCMV infection has been shown to perturb cell cycle regulation
(8–11), which leads to changes in cellular gene expression. The
complex virus–host cell interaction has the potential to modulate
the expression of cellular genes dramatically.
Relatively few cellular genes have been identified whose ac-
tivity changes in HCMV-infected cells (12). Recently, differential
display analysis was used to identify 15 interferon-inducible genes
that are activated by the virus subsequent to infection (13).
However, this screen identified only genes whose mRNA levels
changed dramatically, and the screen was not performed under a
variety of conditions, given its labor-intensive nature. In contrast
to differential display, the DNA array assay is performed easily
and can detect subtle changes in mRNA levels. We report the
identification of 258 cellular mRNAs whose level changes by a
factor of 4 or more before the onset of HCMV DNA replication.
MATERIALS AND METHODS
Cells and Viruses. Primary human foreskin fibroblasts at
passage 10–15 were cultured in DMEM containing 10% fetal calf
serum. After the cells remained at confluence for 3 days, they
were infected at a multiplicity of 3 plaque-forming units per cell
with HCMV AD169 or Toledo virions that were purified as
described (14).
Sample Preparation and Analysis with DNA Arrays. Biotin-
ylated single-stranded antisense RNA samples for hybridization
were prepared as described (15) with minor modifications. Total
cellular RNA was prepared by using the TRIZOL Reagent
(GIBCOyBRL), polyadenylated RNA was isolated, and portions
(5 mg) were used as the template for the first strand cDNA
synthesis in a reaction that was primed with oligo(dT) containing
a T7 RNA polymerase promoter sequence at its 59 end [59-GG-
CCAGTGAATTGTAATACGACTCACTATAGGGAGGC-
GG(T)24-39]. The second cDNA strand was synthesized by using
Escherichia coli DNA polymerase I and ligase. The resulting
cDNA (0.5–1 mg) was used as template to make a biotinylated
RNA probe by in vitro transcription using the T7 Megascript
System (Ambion, Austin, TX). Unincorporated nucleotides were
removed by using a G-50 Quick Spin Column (Boehringer
Mannheim). The labeled RNA was fragmented to an average size
of 50–100 bases by incubating at 94°C for 30 min in buffer
containing 40 mM TriszAc (pH 8.1), 100 mM KOAc, and 30 mM
MgOAc. The hybridization (15 h), washing, and staining proto-
cols were as described (15) and used a set of four human gene
chips (HUM6000 A, B, C, and D, Affymetrix, Santa Clara, CA).
The DNA arrays were scanned by using a confocal scanner
manufactured for Affymetrix by Molecular Dynamics.
Data Analysis. The data collected in each hybridization ex-
periment was processed by using the GENECHIP software supplied
with the Affymetrix instrumentation system. To evaluate whether
RNA corresponding to each of the 6,600 genes encoded on the
array was detectable or undetectable, a number of parameters
were evaluated (15, 16), including the number of probe pairs
interrogating each gene in which the intensity of the perfect match
hybridization reaction exceeded that of the mismatch hybridization
signal and the perfect matchymismatch ratios for each set of probe
pairs. To determine the quantitative amounts of RNA from each
gene, the average of the differences (perfect match minus mis-
match) for each probe pair in a probe set was calculated as well as
the average differences across the probe sets. The cutoff thresh-
olds were determined empirically to be conservative; that is, they
minimized false positives. The change in the level of expression
for any gene was considered significant if the change in the
average differences across the probe sets was .3-fold.
RNA Analysis by Northern Blot. GENECHIP results were con-
firmed by Northern blot assay. Total RNA (3 mg) from mock-
infected cells or cells infected with the HCMV AD169 or Toledo
strains was subjected to electrophoresis, was blotted to a mem-
brane, and was probed with random hexanucleotide-primed
32P-labeled cDNA fragments from IMAGE (Genome Systems, St.
Louis).
RESULTS
The gene chip assay used a set of four probe arrays that
together include oligonucleotides corresponding to .6,600
human mRNAs (16). Each array (1.6 cm2) contains .65,000
features, and a different oligodeoxyribonucleotide (25 bases) is
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synthesized on the surface of the derivatized glass wafer within
the boundaries of each feature by using light-sensitive chemistry
(17–21). The arrays contain 20 pairs of oligonucleotide probes
corresponding to each RNA that is interrogated. Each probe pair
consists of one 25-mer that is a perfect complement to the RNA
(a perfect match probe) and a companion oligonucleotide that
carries a single base difference in a central position (a mismatch
probe). The mismatch probes serve as internal controls for
hybridization specificity. Empirically derived rules used for the
selection of oligonucleotide probes with the best sensitivity and
specificity have been described (16).
RNA samples were prepared for analysis at 40 min, 8 h, and
24 h after mock infection or HCMV (strain AD169) infection of
primary human fibroblasts. Under these conditions, HCMV
DNA replication begins between 24 and 36 h after infection (10),
and the complete viral replication cycle requires '72 h. So, all of
the time points assayed were relatively early in the HCMV
replication cycle. Biotinylated RNA target samples were gener-
ated by in vitro transcription of cDNA that was prepared from
cellular mRNA by using an oligo(dT) primer with a T7 polymer-
ase promoter at its 59 end. This protocol amplifies the mRNA
population in an unbiased and reproducible fashion (16). The
resulting antisense RNA was fragmented to an average size of 50
to 100 bases and was hybridized to the oligonucleotide probe
arrays, and then the arrays were reacted with phycoerythrin-
conjugated streptavidin. The intensity of the fluorescent signal
within each feature then was quantified by using a confocal
scanner (Affymetrix). Previous studies have demonstrated that
the fluorescent signal is linearly related to the concentration of
RNA target within the range of '1 (1 part in 300,000) to nearly
103 copies of RNA per cell (16). Above 103 copies per cell, the
signal continues to increase but in a nonlinear fashion because the
oligonucleotide probes begin to saturate. RNAs corresponding to
3,020–3,380 of the 6,600 genes were detected in different exper-
iments. The range is caused in part by virus-induced changes.
However, much of the variation is caused by mRNAs expressed
at the level of 1–10 copies per cell, scoring as present in one assay
and absent in another experiment.
The DNA arrays contain a set of 198 oligonucleotides corre-
sponding to sequences spread across the entire length of the
glyceraldehyde-3-phosphate dehydrogenase mRNA. The target
RNAs prepared at 8 h after infection with HCMV (Fig. 1A) or
after mock infection (data not shown) hybridized to the complete
glyceraldehyde-3-phosphate dehydrogenase probe set. The arrays
also included oligonucleotides spanning the actin mRNA and
target RNAs hybridized to this complete probe set, as well (data
not shown). These controls demonstrated that the target RNA
preparations span the entire length of the test gene and provided
confidence that the cDNA synthesis and subsequent in vitro
transcription generated target RNAs representative of the input
mRNA.
The reproducibility of hybridization signals produced by inde-
pendent preparations of target RNAs also was tested. Biotin-
ylated target RNA was prepared from mock-infected cells (Fig.
1B) or at 8 h after infection (Fig. 1C) and was hybridized to
different sets of arrays. The concentration of only one cellular
mRNA differed by a factor of .3 in the replicate experiments
(Fig. 1B). This control demonstrates that the hybridization signals
observed in independent experiments are highly reproducible.
Further, the two preparations of infected cell target RNAs were
prepared from infected primary fibroblasts derived from two
different tissue samples, ruling out the possibility that changes in
RNA levels might reflect genetic differences in the host cells.
Differences .3-fold observed for hybridization signals in com-
parisons of mock-infected versus infected cells should identify
genes whose mRNA levels change after infection.
When target RNA preparations were compared at 40 min after
mock or virus infection, the level of 27 mRNAs had changed in
response to infection by a factor of 3 or more; at 8 and 24 h after
infection, the number of altered mRNAs increased to 93 and 364,
respectively (Fig. 2). Applying a more stringent 4-fold change as
the cut off, we generated a set of 258 mRNAs for further analysis
(Table 1). Of these mRNAs, 124 increased, and 134 decreased
after infection. We assume that most changes resulted from
altered transcriptional regulation, but we have not yet tested this
FIG. 1. Characterization of RNA target samples and reproducibility
of array-based hybridization results. (A) Probe pairs (82, 68, and 51 pairs)
were used to interrogate the 59, middle, and 39 portions of the glyceral-
dehyde-3-phosphate dehydrogenase mRNA, which is expressed consti-
tutively in fibroblasts. (B and C) Plots comparing the average difference
intensities in fluorescent signal (Avg. Diff. Intensities) of the 20 probe
pairs interrogating each of the genes present in two independent exper-
iments performed on the mock-infected cells (B) or cells at 8 h after
infection (C). The parallel lines flanking the center diagonal line indicate
3-, 10-, and 30-fold changes in intensity. With the exception of the
thombospondin 1 gene in the mock-infected control, all genes demon-
strated an average difference in their fluorescent intensities of ,3-fold.
FIG. 2. Global survey of the differences in mRNA levels after HCMV
infection. The plots show the variation in fluorescent signal intensities
(Avg. Diff. Intensities) between mock-infected cells and cells at 40 min,
8 h, and 24 h after infection. Changes in expression of 3-, 10-, and 30-fold
are highlighted by the parallel lines flanking the center diagonal line.
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Actinytubulinymyosin
X06956 a-tubulin 24 h, 63 U 3
R59199 est 5 X79535 2 b tubulin 24 h, 43 U 3
Z24727 tropomyosin isoform 24 h, 43 D 3
T92451 est 5 M12125 2 tropomyosin 24 h, 53 D 3
X05276 fibroblast tropomyosin TM30 (pl) 24 h, 43 D 3
T60155 est 5 J05192 2 a-actin (ACTA) 24 h, 113 D 3
M19283 g-actin 24 h, 43 D 3
X54163 cardiac troponin I 24 h, 53 D 3
H44011 myosin heavy chain 8 h, 53 D 3
T55741 est 5 X85337 2 myosin light chain kinase (MLCK) 24 h, 63 D 3
X53416 actin-binding protein (filamin) (ABP-280) 24 h, 53 D 1
T97948 neutral calponin 24 h, 153 D 3
Cell cycle
L49231 retinoblastoma susceptibility protein (RB1) 24 h, 123 U 3
X59798 PRAD1 mRNA for cyclin 24 h, 93 D 3
D13891 Id-2H 8 h, 24 h, 43 D 3
L13698 gas-1 (growth-arrest-specific gene) 8 h, 24 h, 153, 63 D 1
X62048 Wee1 hu 8 h, 24 h, 53 D 3
H50438 est 5 M81934 2 cdc25B 8 h, 43 D 3
U09477 53BP1 p53-binding protein 8 h, 53 D 3
Coagulation
R16659 est 5 L27624 and AC002076 2 TFPI-2 24 h, 83 U 1
M59499 lipoprotein-associated coagulation inhibitor 8 h, 63 D 3
M14083 b-migrating plasminogen activator inhibitor I 24 h, 43 D 3
J02933 blood coagulation factor VII gene 24 h, 53 D 3
Complement
M31516 decay-accelerating factor (DAF) 8, 24 h, 43, 53 U 1
T54547 est 5 M84526 2 adipsinycomplement factor D 24 h, 73 D 3
T69603 est 5 M14058 2 complement c1r component 24 h, 43 D 3
R12676 est 5 M65292 2 1.4 kilobase mRNA of
complement factor H
409, 43 D 3
Cytokinaseyreceptors
M21121 rantes 8 h, 63 U 2
M29150 interleukin 6 8 h, 103 U 3
X58377 interleukin 11 (IL-11) 8, 24 h, 43, 113 U 1
M29696 interleulin 7 (IL-7) receptor, a chain 24 h, 43 U 1
U02020 pre-B cell enhancing factor (PBEF) 8 h, 24 h, 43 U 3
T61446 A20 8 h, 43 U 3
L35263 CSaids binding protein (CSBP1) 8 h, 73 D 3
M58286 tumor necrosis factor receptor 8 h, 24 h, 43, 53 D 1
H14506 est 5 L36034 2 pre-B cell stimulating factor 24 h, 43 D 1
X72012 endoglin 8 h, 233 D 3
Extracellular matrix and cell adhesion
L36531 integrin a 8 subunit 409, 63 U 3
M80244 E16, an integral membrane protein 409, 43 U 3
X14787 thrombospondin 1 (TSP1) 24 h, 213 D 1
L12350 thrombospondin 2 (TSP2) 24 h, 133 D 3
X05231 collagenase 409, 8 h, 43, 73 D 3
L25285 collagen a-1 type XV (COL15A1) 24 h, 133 D 3
J03464 collagen a-2 type I 24 h, 143 D 3
M11718 collagen a-2 type V 24 h, 83 D 3
M34570 collagen a-2 type VI 24 h, 63 D 3
T51558 est 5 K01228 2 procollagen a 1 (I) chain 24 h, 63 D 3
X06700 pro-a1 (III) collagen 24 h, 163 D 1
L16895 lysyl oxidase, an extracellular copper enzyme 24 h, 43 D 3
X53743 fibulin-1 C 2 a secreted glycoprotein 409, 8 h, 73, 53 D 3
U34976 g-sarcoglycan, a dystrophin-associated protein 24 h, 63 D 3
U14394 Tissue inhibitor of metalloproteinases-3 (TIMP3) 24 h, 6–83 D 3
R32771 est 5 U37791 2 rasi-1 matrix metalloproteinase 8 h, 24 h, 53, 93 D 3
U03877 extracellular protein (S1–5) 24 h, 43 D 3
L34056 cadherin-11 24 h, 93 D 3
GTP binding proteins
H67367 est 5 D38076 2 RanBP1 (Ran-binding protein 1) 24 h, 53 U 3
T93295 est:homo. of L20294-mouse GTP-binding protein 24 h, 43 U 3
X75593 rab 13 24 h, 93 D 3
R53966 est 5 Z22641 2 a2-chimaerin 24 h, 83 D 3
H19201 est: homo. to mouse L07924 2 gua. nucl.
disso. stim.
8 h, 93 D 3
Heat shock and stress-inducible proteins
R08183 est 5 X75821, U07550 2 chaperonin 10 24 h, 83 U 3
T66307 heat shock 70kDa protein 1 24 h, 113 U 3
M86752 transformation-sensitive protein 24 h, 83 U 3
L08069 heat shock protein, E. coli DnaJ homologue 8 h, 43 U 3
H55758 est 5 M14328 a enolase 24 h, 153 U 3
T93272 est 5 M62829 early growth response protein 1 8, 24 h, 53, 63 U 1
T51856 est: homo. to stress-inducible chaperone
mt-GrpE#1
24 h, 43 U 3
X79066 ERF-1 8 h, 43 D 3
Interferon
M24594 interferon-stimulated genes 54K (isg54K) 8 h, 24 h, 193, 53 U 2
M87434 71-kDa 2959 oligoadenylate synthetase 8 h, 63 U 2
X02875 (29-59) oligo A synthetase E (1.8 kilobase RNA) 8 h, 24 h, 153, 73 U 2
X02874 (29-59) oligo A synthetase E (1.6 kilobase RNA) 8 h, 83 U 2
M87284 69-kDa 2959 oligoadenylate synthetase 8 h, 83 U 2
X02530 g-interferon inducible early response gene 8 h, 343 U 1
L05072 interferon regulatory factor 1 (IRF-1) 24 h, 73 U 2
X15949 interferon regulatory factor-2 (IRF-2) 8 h, 53 U 2
X67325 interferon-a inducible gene; p27 gene 24 h, 73 U 2
H05300 interferon-induced guanylate-binding protein 1 8 h, 24 h, 173, 93 U 2
M55542 guanylate binding protein isoform II 8 h, 93 U 2
D31887 KIAA0062 (cig19) 8 h, 24 h, 43 U 2
X82200 interferon inducible gene staf50 24 h, 143 U 1
X02492 interferon-induced protein 6-16 8 h, 24 h, 43, 53 U 2
R34698 interferon-inducible protein 9-27 8 h, 24 h, 63 U 2
M13755 interferon-induced 17-kDay15-kDa protein 8 h, 24 h, 1503 U 2
M28622 interferon b 8 h, 243 U 2
X17668 indoleamine 2,3-dioxygenase 8 h, 473 U 1
M33882 MxA 8 h, 24 h, 473, 53 U 2
M30818 MxB 8 h, 303 U 2
X56841 HLA-E gene 8 h, 24 h, 63 U 1
T50250 est: homo. to U51904, mouse IFN a-treated
mRNA
24 h, 323 U 1
M60618 nuclear autoantigen Sp100 8 h, 53 U 2
M73778 PML-1 8 h, 63 U 2
Kinase/phosphate
R39857 est 5 X97630 2 serineythreonine protein
kinase EMK
24 h, 43 U 3
H02889 est 5 Y11366 IMPA gene 24 h, 83 U 3
U25994 cell death protein (RIP protein kinase) 8 h, 43 U 1
D21209 protein tyrosine phosphatase (PTP-BAS, type 1) 24 h, 53 D 1
X77278 HYL tyrosine kinase 24 h, 83 D 3
R60908 est 5 X74764 2 receptor protein tyrosine kinase 24 h, 213 D 1
H65441 est 5 U78027, L35265 2 Bruton’s tyrosine kinase 24 h, 73 D 3
X16416 proto-oncogene tyrosine-protein kinase (abl) 24 h, 43 D 1
Lamins
M55210 laminin B2 chain 24 h, 83 D 3
X79683 b2 laminin 24 h, 53 D 3
R43734 S78569 2 laminin a 4 chain 24 h, 63 D 3
T55218 est 5 M13452 or M13451 2 lamin A or C 8 h, 263 D 3
Ligands and receptors
L13740 TR3 orphan receptor 8, 24 h, 53, 463 U 1
U12767 mitogen-induced nuclear orphan receptor 8 h, 53 U 3
M77140 pro-galanin 24 h, 203 U 1
M63888 heparin-binding growth factor receptor 24 h, 93 U 3
T70920 est 5 M88279 2 immunophilin (FKBP52) 24 h, 83 U 3
M20132 androgen receptor (AR) 8 h, 43 D 3
M19481 follistatin 24 h, 163 D 1
T71662 est 5 M14118 2 insulin-like growth factor
(IGF-II)
24 h, 43 D 1
M35878 insulin-like growth factor-binding protein-3 24 h, 43 D 3
M65062 insulin-like growth factor-binding protein-5 24 h, 53 D 3
M35410 insulin-like growth factor-binding protein 2 409, 8 h, 53, 113 D 3
X04434 insulin-like growth factor I receptor 409, 8 h, 24 h, 43 D 3
L07594 transforming growth factor b type III receptor 8 h, 24 h, 43, 63 D 1
M21574 platelet-derived growth factor receptor a 24 h, 253 D 1
H88938 est 5 M60828 M25295 2 keratinocyte growth
factor
8 h, 43 D 3
X62381 activin receptor; growth factor-like receptor 8 h, 63 D 3
R45296 est 5 U67784 2 orphan G protein-coupled
receptor
24 h, 63 D 3
X02157 fetal erythropoietin 24 h, 43 D 3
M64497 apolipoprotein A1 regulatory protein (ARP-1) 8 h, 4–53 D 1
L11708 17 b hydroxysteroid dehydrogenase type 2 24 h, 73 D 3
L00352 low density lipoprotein (LDL) receptor 8 h, 24 h, 53, 63 D 3
M10065 apolipoprotein E 409, 8 h, 73, 263 D 3
Prostaglandin synthesis
U04636 cyclooxygenase-2 (cox2) 8 h, 73 U 2
M72393 cystosolic phospholipase A2 (cPLA2) 8 h, 24 h, 123, 73 U 3
X05908 lipocortin 24 h, 93 D 3
D38145 prostacyclin synthase 24 h, 43 D 3
Protein degradation
T56244 est 5 D26599 2 proteasome subunit HsC7-I 24 h, 63 U 3
T54276 proteasome subunit LMP7 (allele LMP7C) 8 h, 43 U 3
T92259 proteasome component IOTA chain 24 h, 53 U 3
D00762 proteasome component HC8 24 h, 63 U 3
D00760 proteasome component C3 24 h, 53 U 3
H05893 26S proteasome subunit p97 24 h, 43 U 3
L02426 26S protease (S4) regulatory subunit 24 h, 163 U 3
M91670 ubiquitin carrier protein (E2-EPF) 24 h, 43 U 1
R67921 est 5 D55696 2 putative cysteine protease 8 h, 43 U 3
T56256 est 5 U20657 2 ubiquitin protease proto-oncogene 8 h, 43 D 3
J03589 ubiquitin-like protein (GdX) 24 h, 73 D 3
T50500 est 5 Z22658 2 a placental thrombin inhibitor
(PTI)
24 h, 43 D 3
Protooncogenes
X89985 BCL7B gene 8 h, 24 h, 53 U 1
H48122 est 5 U43746, breast cancer susceptibility
(BRCA2)
8 h, 43 U 1
M83751 arginine-rich protein (ARP) 24 h, 113 U 3
M27903 pim-1 proto-oncogene 24 h, 163 U 3
T53138 est 5 Y11306 2 hTCF-4 8 h, 43 D 3
X16416 proto-oncogene tyrosine-protein kinase (abl) 24 h, 43 D 1
D43969 AML1c protein 8 h, 24 h, 43 D 3
X82209 MN1 8 h, 24 h, 73 D 3
Splicing factors
X13482 U2 small nuclear ribonucleoprotein A9 24 h, 43 U 3
M15841 U2 small nuclear RNA-associated B0 24 h, 43 U 3
R41349 splicing factor, arginineyserine-rich 7 (SFRS7) 24 h, 103 U 3
Transcription factors
R55041 est 5 J03161 2 serum response factor (SRF) 24 h, 53 U 3
H46624 est: homology to mouse AB012276 2ATFx 8 h, 43 U 3
M97676 homeobox protein (HOX7) 8 h, 43 U 1
R26139 est 5 X59268 2 TFIIB 8 h, 83 U 1
M69043 MAD-3, encodes an I k B-like protein 24 h, 103 U 1
R26146 NF-kB p105 subunit 24 h, 43 U 3
U09825 acid finger protein (AFP) 8 h, 24 h, 53, 73 U 1
H88261 est 5 U90304 iroquois-class homeodomain protein 8 h, 43 U 3
Z29678 mitF 24 h, 83 D 3
X03348 b-glucocorticoid receptor 8 h, 24 h, 43 D 3
M83667 NF-IL6-b protein 8 h, 43 D 1
X57435 transcription factor AP-4 8 h, 24, 43 D 3
M36711 sequence-specific DNA-binding protein (AP-2) 8 h, 63 D 3
Y00345 polyA binding protein 24 h, 53 D 3
R39209 est 5 X65644 2 MBP-2 for MHC binding
protein 2
24 h, 53 D 3
L19872 aryl hydrocarbon receptor (AhR) 8 h, 24 h, 83, 53 D 3
Translation factors
R72300 est 5 U17969 2 translation initiation factor
eIF-5A
24 h, 1493 U 1
H04333 est 5 U49436 2 translation initiation factor 5
(eIF5)
24 h, 43 U 3
T69446 est 5 D13748 2 initiation factor 4A-1 (eIF-4A1) 24 h, 363 U 3
L18960 translation initiation factor (eIF-4C) 24 h, 393 U 3
H01943 eukaryotic initiation factor 4E (eIF-4E) 24 h, 43 U 3
X62570 IFP53, trypotophanyl-tRNA synthetase 8 h, 8003 U 1
M81592 g-glutamyl carboxylase (hGC) 24 h, 53 U 3
Z12830 SSR (signal-sequence receptor) a subunit 24 h, 53 U 3
R60357 alanyl tRNA synthetase 8 h, 53 D 2
D31762 KIAA0057 gene 2 homolog of TRAMP 24 h, 83 D 3
Miscellaneous
M34551 52k autoantigen in RoySSA ribonucleoprotein
compl.
8 h, 24 h, 123 U 3
U33286 chromosome segregation gene homolog CAS 24 h, 43 U 3
T88721 est 5 U52100, X94770 2 XMP mRNA 24 h, 43 U 3
M26697 nucleolar phosphoprotein B23 24 h, 123 U 3
J05682 subunit C of V-ATPase (vat C) 24 h, 83 U 1
M22349 neuron-specific g-2 enolase 24 h, 63 U 3
M24470 glucose-6-phosphate dehydrogenase 8 h, 24 h, 43, 63 U 3
T47964 purine nucleoside phosphorylase 24 h, 83 U 1
U07681 NAD(H)-specific isocitrate dehydrogenase a
subunit
24 h, 93 U 3
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Table 1. mRNAs that increase or decrease $4-fold after
HCMV infection
Table 1. Continued
(Table continues on the opposite page)
supposition. We confirmed 49 (40%) of the mRNAs predicted to
be increased and 23 (17%) of the mRNAs predicted to be
decreased either by Northern blot analysis of independent RNA
preparations (representative results in Fig. 3) or by reference to
earlier studies (12, 13) that demonstrated a change. All attempts
to confirm a predicted alteration in the group of 258 mRNAs
were successful.
We assayed changes in mRNA levels for a total of 58 genes in
this study by Northern blot. When we performed these assays, we
included RNA preparations from cells infected with HCMV
strain AD169, the laboratory-adapted strain used for the DNA
array analysis, and HCMV strain Toledo, a clinical isolate that has
not been passaged extensively in cultured cells (22). We observed
the same alteration in mRNA level for both infections (repre-
sentative results in Fig. 3). Although we might find some differ-
ences as more genes are assayed, our results to date argue that the
laboratory and clinical isolates of HCMV alter cellular gene
expression in a similar fashion.
DISCUSSION
HCMV replicates in many different cell types within its infected
host, some of which might respond to infection differently than
the primary fibroblasts we have studied here. Keeping this caveat
in mind, we nevertheless can speculate that several of the cellular
genes whose mRNA levels change after infection of fibroblasts
might profoundly influence HCMV replication and pathogenesis.
HLA-E mRNAs. To protect infected cells from cytotoxic T
lymphocytes, multiple HCMV gene products act to reduce cell
surface expression of classical class I major histocompatibility
complex molecules (23–28). Although these viral activities pro-
tect infected cells from cytotoxic T lymphocytes, they also have
the potential to render infected cells susceptible to natural killer
(NK) cells that can recognize and destroy cells that no longer
express class I major histocompatibility complex molecules.
HLA-E mRNA was induced by a factor of 6 at 24 h after infection
(Table 1; Fig. 3) whereas HLA-A, HLA-D, and HLA-G family
members that were represented in the DNA arrays were not
changed (data not shown). HLA-E is a nonclassical class I
molecule whose cell surface expression requires that it bind
peptides derived from the signal sequences of other class I
molecules (HLA-A, -B, and -C) (29). Recently, it has been shown
that NK cells recognize and spare target cells expressing HLA-E
on their surface (30, 31). This recognition is mediated by the NK
cell CD94-NKG2 cell surface receptor. Assuming that the ele-
vated mRNA leads to elevated cell surface expression of HLA-E,
this modulation should protect virus-infected cells from NK cell
killing. This would be the second mechanism by which HCMV
avoids NK cell surveillance. The viral UL18 protein is a major
histocompatibility complex homologue that engages another
receptor (NKIR) on the NK cell to avoid attack (32).
RoySSA 52-kDa mRNA. HCMV-infected cells contain en-
hanced levels of the RoySSA 52-kDa protein mRNA (Table 1).
The mRNA encoding this protein, which is a constituent of a
ribonucleoprotein complex, was induced by a factor of 12 at 24 h
after infection (Fig. 3). Autoantibodies to this protein are found
R42235 est 5 X56452 2 CYP2C gene for cytochrome P450 24 h, 63 U 1
H53120 est 5 D12676 2 lysosomal sialoglycoprotein 24 h, 43 U 3
J00123 enkephalin gene 24 h, 83 U 3
H28131 est 5 M64784 2 platelet 6-phosphofructokinase 24 h, 203 U 3
R42244 est 5 X57522 2 antigen peptide transporter 1 24 h, 63 U 3
R26294 est 5 AF017732 2 chromosome 2 cosmids 24 h, 43 U 3
L25270 XE169 24 h, 43 U 3
U01833 a putative nucleotide-binding protein 24 h, 73 U 1
H72850 est 5 X56351 5 2 aminolevulinate synthase 8 h, 24 h, 43 U 3
U29195 neuronal pentraxin II (NPTX2) 24 h, 73 U 3
U19523 GTP cyclohydrolase I 8 h, 24 h, 43 U 1
H03980 est 5 AB001106 2 glia maturation factor 24 h, 53 U 3
L19779 histone H2A.2 8 h, 73 U 3
X69978 ERCC5 excision repair protein 8 h, 53 D 3
X65024 xeroderma pigmentosum group C compl. factor 24 h, 43 D 3
R60318 est 5 AF022813 2 tetraspan (NAG-2) 24 h, 283 D 3
H87106 est 5 AF043906 2 T245 protein (T245) 24 h, 43 D 3
U14650 platelet-endothelial tetraspan antigen 3 24 h, 233 D 3
L13385 Miller-Dieker lissencephaly protein (LIS1) 24 h, 43 D 3
L35263 CSaids binding protein (CSBP1) 8 h, 73 D 3
D10522 80K-L protein 2 a major substrate for protein
kinase C
8 h, 43 D 1
J02814 chondroitin sulfate proteoglycan core protein 24 h, 63 D 3
X75090 HLA-DR associated protein I (PHAPI) 8 h, 43 D 3
U08092 histamine N-methyltransferase (HNMT) 8 h, 43 D 3
D14874 adrenomedullin 8 h, 24 h, 183, 43 D 1
H80262 est 5 X15422 2 mannose-binding protein C 24 h, 83 D 3
K88575 est 5 U55017 M86521 2 transketolase (TKT) 24 h, 53 D 1
M13994 cytoscolic aldehyde dehydrogenase (ALDH1) 24 h, 5–73 D 1
M22324 aminopeptidase NyCD13 mRNA 24 h, 43 D 3
M12996 glucose-6-phosphate dehydrogenase (G6PD) 24 h, 53 D 1
T52343 est 5 Y00433 2 glutathione peroxidase 24 h, 43 D 3
T64167 est 5 dihydrodiol dehydrogenase isozyme DD2 8 h, 24 h, 43 D 3
X58022 Corticotropin-releasing factor binding protein 24 h, 43 D 3
U03688 Dioxin-inducible cytochrome P450 (CYPIB1) 24 h, 113 D 3
H67764 est 5 U55764 2 estrogen sulfotransferase 24 h, 43 D 3
D00137 class I alcohol dehydrogenase b-1 subunit 8 h, 53 D 3
M77836 pyrroline 5-carboxylate reductase (EC 1.5.1.2) 24, 153 D 3
T57002 est 5 M29038 2 stem cell protein (SCL) 24 h, 4X D 3
D13665 est 5 D13665 2 osteoblast specific factor 2
(OSF-2p1)
24 h, 73 D 3
M22490 bone morphogenetic protein-2B (BMP-2B) 8 h, 43 D 3
M95787 22kDa smooth muscle protein (SM22) 24 h, 53 D 3
Z11559 iron regulatory factor (IRF) 8 h, 24 h, 53 D 3
T63612 ferritin heavy chain 8 h, 43 D 3
T72863 est 5 M10119 2 ferritin light subunit 24 h, 2873 D 3
R56881 est 5 U61166 2 Xenopus laeyis intersectin
homolog
8 h, 43 D 3
T63052 est: homolog of Mus musculus X52102 24 h, 53 U 3
D14663 KIAA0107 gene 24 h, 43 U 3
R61352 est 5 D42085 KIAA0095 gene 24 h, 63 U 3
U16954 AF1q 24 h, 73 U 3
R98335 est 5 L13744 AF-9 (unknown function) 8 h, 53 U 3
R01072 est: unknown 24 h, 53 U 3
R10664 est: unknown 24 h, 73 U 3
H24245 est: unknown 24 h, 53 U 3
H11036 est: unknown 24 h, 63 U 3
R42152 est: unknown 24 h, 73 U 3
R74454 est: unknown 8 h, 24 h, 43 U 3
R54359 est: unknown 24 h, 103 U 1
R01124 est: unknown 24 h, 153 U 3
R56443 est: unknown 24 h, 73 U 3
T70251 est: unknown 409, 8 h, 43 D 3
H92205 est: unknown 8 h, 43 D 3
T89666 est: unknown 8 h, 43 D 3
H13281 est: unknown 24 h, 153 D 3
R60741 est: unknown 8 h, 43 D 3
H16597 est: unknown 24 h, 43 D 3
R40403 est: unknown 24 h, 63 D 3
H78404 est: unknown 8 h, 43 D 3
T48692 est: unknown 8 h, 24 h, 63 D 3
H40677 est: unknown 8 h, 63 D 3
H86071 est: homology to mouse AF003234 8 h, 53 D 3
Identity of columns, from left to right: GenBank accession number;
name of gene encoding mRNA; time(s) after infection when a change
in mRNA level was observed plus fold change; increase (U) or
decrease (D) in steady state level of RNA; and gene chip results
confirmed in this report by Northern blot analysis (1), confirmed by
another literature report (2), or not confirmed (3).
FIG. 3. Representative Northern blot analyses confirming changes in
mRNA levels predicted by DNA array assay. Cultures of primary human
diploid fibroblasts were infected with HCMV strain AD169 or Toledo,
and total cellular RNA was examined by Northern blot analysis at 40 min,
8 h, and 24 h after infection. Genes to which the probes correspond are
identified to the right of the autoradiograms. M, mock-infected cells.
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in a variety of connective tissue diseases: commonly in systemic
lupus erythematosis, neonatal lupus erythematosis, and Sjogren’s
syndrome and less frequently in rheumatoid arthritis (33). There
is good evidence that these autoantibodies play a direct patho-
genic role in neonatal lupus erythematosis and subacute cutane-
ous lupus erythematosis (33, 34). However, the mechanism by
which the immune system initially responds to RoySSA and other
intracellular self-antigens is not clear. One popular hypothesis
suggests that molecular mimicry is an important initiating mech-
anism; that is, aspects of the immune response to a microbe
cross-react with self-proteins (35). Conceivably, overexpression of
a commonly targeted autoantigen, such as the RoySSA antigen
in HCMV-infected cells, also could favor an autoimmune re-
sponse. Although the RoySSA 52-kDa antigen normally is found
in the nucleus and cytoplasm, it can be detected on the surface
of peripheral lymphocytes that have been stressed by heat shock
or treatment with ultraviolet light (36). Perhaps stress induced by
HCMV infection also leads to cell surface presentation of Roy
SSA, facilitating an autoimmune response to the overexpressed
antigen. Murine cytomegalovirus has been shown to induce
autoimmune antibodies in infected mice (37–40), although Roy
SSA antibodies were not monitored in these studies.
Lipocortin 1, Cytosolic Phospholipase A2 (cPLA2), and Cy-
clooxygenase 2 (COX-2) mRNAs. Multiple constituents of the
pathway that produces prostaglandin E2 from arachidonic acid
are modulated by HCMV (Table 1). cPLA2 mRNA increased by
a factor of 12, and COX-2 mRNA was elevated by a factor of 7
at 24 h after infection. Lipocortin 1, also known as annexin I,
mRNA decreased by a factor of 9 at 24 h after infection. When
cPLA2 is activated by phosphorylation, it translocates to mem-
branes, where it selectively cleaves and releases arachidonic acid;
then, COX-2 converts it to prostaglandin E2. Lipocortin 1 inhibits
the activation of cPLA2 (41). Thus, in HCMV-infected fibro-
blasts, the synthesis of prostaglandin E2 is activated by the
induction of cPLA2 and COX-2 and the inhibition of the negative
regulator lipocortin 1, assuming that the changes in mRNA levels
translate to changes in active proteins. Further, HCMV infection
has been shown to activate latent cPLA2 by inducing its phos-
phorylation (42). Thus, this pathway is induced strongly at both
the transcriptional and posttranslational levels after infection, and
this should lead to a marked increase in the production of
prostaglandin E2. Prostaglandins serve as second messengers to
stimulate a variety of responses, including inflammation. Perhaps
the activation of this pathway is a cellular reaction to HCMV
infection designed to induce a cell-mediated response that will kill
the infected cell and thereby inhibit spread of the infection.
Alternatively, one might speculate that the virus either induces
the pathway or fails to antagonize the induction as a strategy to
facilitate spread of the virus within the infected host. Inflamma-
tion might serve to lure monocytes and monocytic precursors to
the vicinity of the infected cells, where they can be infected. Cells
of the monocytic lineage harbor HCMV on a long-term basis in
a latent state (43–45).
It is possible that the concerted changes in cPLA2, COX-2, and
lipocortin 1 are an indirect effect of HCMV gene action. Inter-
leukin 1b has been shown to regulate this set of genes (46) in the
same manner as seen in infected cells. Although several reports
have suggested that interleukin 1b activity is decreased in cultures
of HCMV-infected monocytes (47, 48), the HCMV IE1 gene has
been shown to induce the accumulation of interleukin 1b mRNA
in transfected monocytes (49, 50). The interleukin 1b gene was
not included in the oligonucleotide array assayed in this report, so
we do not know if its mRNA is induced by infection of fibroblasts.
Thombospondin-1 mRNA. Thombospondin-1 is a calcium-
binding protein released on platelet activation (51). It is a
constituent of the extracellular matrix that regulates cell growth
and differentiation, and it might potentiate tumor progression
(52). Recently, thombospondin 1-deficient mice have been pro-
duced (53) whose lungs exhibit acute and chronic cell infiltrates
with increased fibroblastic and epithelial cell proliferation, matrix
deposition, and diffuse alveolar hemorrhage characteristic of
pneumonia. Thombospondin-1 mRNA is reduced by a factor of
21 by 24 h after infection with HCMV (Table 1). Replication in
the lung that leads to pneumonia is one of the principle conse-
quences of active HCMV infection in immunosuppressed indi-
viduals (54). Given the phenotype of thombospondin 1-deficient
mice, one can speculate that the reduction in this mRNA might
contribute to pneumonia induced by acute HCMV infection.
Microphthalmia-Associated Transcription Factor (MITF)
mRNA. MITF is the product of the microphthalmia gene. Mice
have been described with a variety of mutations in this gene (55),
and the most severe manifestations of the mutations include
microphthalmia, oeteopetrosis, and deafness. In the human,
MITF mutations were identified in two families afflicted with
Waardenberg syndrome type 2, which causes hearing loss and
patchy pigmentation of the eyes, hair, and skin (56). Infection of
humans with HCMV early in pregnancy has been reported to
cause anophthalmia (57), and congenital infection of mice with
murine cytomegalovirus can cause microphthalmia (58). Modu-
lation of MITF mRNA levels by the virus could contribute to
these abnormalities. MITF mRNA is reduced by a factor of 4–8
at 24 h after HCMV infection of fibroblasts. Although the
association of HCMV with eye abnormalities appears to be rare,
congenital HCMV infection is a common cause of hearing loss.
Conceivably, HCMV-induced hearing loss is a consequence of an
inhibitory effect on MITF mRNA expression during develop-
ment. This supposition is consistent with the observation that
MITF mutations are associated with hearing loss in the Waar-
denberg syndrome. HCMV potentially could modulate MITF in
cells that are eventually killed or in cells where viral gene
expression does not lead to cell death.
Conclusion. The roles of the cellular genes discussed above in
HCMV replication and pathogenesis remain highly speculative.
Nevertheless, the ability to identify cellular genes whose functions
provide tantalizing hints of potential mechanistic roles in infec-
tious disease processes underscores the utility of gene array
technology in the study of pathogens. The global analysis of
changes in mRNA levels provides a catalog of genes that are
modulated as a result of the host–pathogen interaction and
therefore deserve further scrutiny. DNA array analysis provides
an important new approach for the investigation of pathogenic
mechanisms.
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